Back to Search
Start Over
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
- Source :
-
BMC infectious diseases [BMC Infect Dis] 2020 Jan 29; Vol. 20 (1), pp. 81. Date of Electronic Publication: 2020 Jan 29. - Publication Year :
- 2020
-
Abstract
- Background: Macrophages play a key role in the infection process, and alternatively activated macrophages (M2 polarization) play important roles in persistent infection via the immune escape of pathogens. This suggests that immune escape of pathogens from host immunity is an important factor to consider in treatment failure and multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB). In this study, we investigated the association between macrophage polarization and MDR-TB/XDR-TB and the association between macrophage polarization and the anti-TB drugs used.<br />Methods: iNOS and arginase-1, a surface marker of polarized macrophages, were quantified by immunohistochemical staining and imaging analysis of lung tissues of patients who underwent surgical treatment for pulmonary TB. Drug susceptibility/resistance and the type and timing of anti-tuberculosis drugs used were investigated.<br />Results: The M2-like polarization rate and the ratio of the M2-like polarization rate to the M1-like polarization rate were significantly higher in the MDR-TB/XDR-TB group than in the DS-TB group. The association between a high M2-like polarization rate and MDR-TB/XDR-TB was more pronounced in patients with a low M1-like polarization rate. Younger age and a higher M2-like polarization rate were independent associated factors for MDR-TB/XDR-TB. The M2-like polarization rate was significantly higher in patients who received anti-TB drugs containing pyrazinamide continuously for 4 or 6 weeks than in those who received anti-TB drugs not containing pyrazinamide.<br />Conclusions: The M2-like polarization of macrophages is associated with MDR-TB/XDR-TB and anti-TB drug regimens including pyrazinamide or a combination of pyrazinamide, prothionamide and cycloserine.
- Subjects :
- Adult
Cycloserine administration & dosage
Extensively Drug-Resistant Tuberculosis drug therapy
Extensively Drug-Resistant Tuberculosis microbiology
Female
Humans
Lung immunology
Lung microbiology
Macrophages immunology
Male
Middle Aged
Prothionamide administration & dosage
Pyrazinamide administration & dosage
Treatment Failure
Tuberculosis, Multidrug-Resistant drug therapy
Tuberculosis, Multidrug-Resistant microbiology
Tuberculosis, Pulmonary drug therapy
Tuberculosis, Pulmonary microbiology
Antitubercular Agents administration & dosage
Extensively Drug-Resistant Tuberculosis immunology
Macrophage Activation immunology
Mycobacterium tuberculosis immunology
Tuberculosis, Multidrug-Resistant immunology
Tuberculosis, Pulmonary immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2334
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC infectious diseases
- Publication Type :
- Academic Journal
- Accession number :
- 31996142
- Full Text :
- https://doi.org/10.1186/s12879-020-4802-9